develop
vaccin
play
vital
role
effect
control
sever
fatal
diseas
howev
effect
prophylact
therapeut
vaccin
yet
develop
complet
cure
deadli
diseas
cancer
malaria
hiv
seriou
microbi
infect
thu
suitabl
vaccin
candid
need
design
elicit
appropri
immun
respons
nanotechnolog
found
play
uniqu
role
design
vaccin
provid
enhanc
specif
potenc
nanosc
materi
viruslik
particl
liposom
polymer
nanoparticl
np
protein
np
receiv
consider
attent
past
decad
potenti
carrier
deliveri
vaccin
antigen
adjuv
due
benefici
advantag
like
improv
antigen
stabil
target
deliveri
longtim
releas
antigensadjuv
either
encapsul
within
decor
np
surfac
flexibl
design
nanomedicin
allow
program
immun
respons
therebi
address
mani
challeng
encount
vaccin
develop
biomimet
np
emerg
innov
natur
mimick
biosystem
use
wide
rang
biomed
applic
review
discuss
recent
advanc
biomimet
nanovaccin
use
antibacteri
therapi
antihiv
therapi
antimalari
therapi
antimelittin
therapi
antitumor
immun
immun
system
compris
complex
network
cell
tissu
organ
work
harmoni
protect
bodi
deadli
diseas
immun
system
attack
elimin
foreign
invad
particl
exquisit
specif
diseas
caus
malfunct
underperform
immun
respons
overreact
immun
system
caus
autoimmun
may
lead
destruct
healthi
tissu
underact
immun
system
make
bodi
suscept
infect
vaccin
consist
biolog
agent
resembl
diseasecaus
microorgan
improv
immun
particular
diseas
develop
immun
control
adjust
unbalanc
immun
system
either
overreact
underact
weiner
et
al
describ
first
therapeut
vaccin
autoimmun
develop
vaccin
histor
base
loui
pasteur
isol
inactiv
inject
paradigm
current
vaccin
consid
one
effect
tool
prevent
infecti
diseas
thu
vaccin
develop
bacteri
infect
viral
infect
cancer
consid
signific
mileston
field
medicin
past
tradit
vaccin
made
pathogen
either
kill
inactiv
form
consid
effici
shell
structur
np
form
hydrophob
core
thin
layer
plasma
membran
coat
act
shell
np
variou
cell
membran
use
cloak
synthet
np
topdown
fabric
method
thu
preserv
physicochem
properti
core
synthet
np
maintain
cellular
composit
hydrophil
membran
shell
hu
et
al
report
first
membraneco
np
red
blood
cell
rbc
membran
coat
polymer
np
extrus
mani
type
membran
differ
sourc
rbc
leukocyt
cytotox
tcell
nk
cell
platelet
macrophag
cancer
cell
use
prepar
membraneco
np
anoth
type
biomimet
nanovaccin
selfassembl
protein
known
high
symmetri
stabil
structur
organ
particl
size
nm
selfassembl
protein
np
play
divers
physiolog
role
select
vaccin
carrier
owe
abil
selfassembl
deploy
definit
structur
mimic
natur
microb
architectur
viruslik
particl
vlp
anoth
type
biomimet
nanovaccin
contain
noninfecti
subset
viru
lack
genet
materi
assembl
without
contain
viral
rna
review
discuss
recent
advanc
biomimet
nanovaccin
applic
antibacteri
therapi
antihiv
therapi
antimalari
therapi
antimelittin
therapi
antitumor
immun
biomimet
nanovaccin
includ
biomimet
carrier
load
therapeut
molecul
design
deliv
target
site
figur
show
variou
type
biomimet
np
involv
liposom
protein
np
cellmembran
decor
np
vlp
tabl
describ
differ
type
biomimet
nanovaccin
report
far
along
applic
tabl
alreadi
report
biomimet
nanovaccin
applic
liposom
liposomepolycationdna
np
dna
vaccin
deliveri
plga
np
lipid
antigen
malari
vaccin
deliveri
cancer
cell
membran
lipid
coat
onto
polymer
np
tlr
deliveri
anticanc
vaccin
vlp
avian
retroviru
gag
fusion
protein
intracellular
protein
deliveri
genet
modifi
vlp
antivir
protect
selfassembl
protein
hollow
vault
protein
suppress
lung
cancer
prolifer
cell
membran
decor
np
gastric
epitheli
cell
membran
coat
plga
np
load
antibiot
antibaceri
therapi
bacteri
membran
coat
gold
np
antibacteri
immun
liposom
liposom
biomimet
product
form
dispers
phospholipid
water
occur
either
unilamellar
vesicl
singl
phospholipid
bilay
multilamellar
vesicl
sever
concentr
phospholipid
shell
separ
differ
layer
water
liposom
modifi
incorpor
hydrophob
hydrophil
molecul
phospholipid
bilay
aqueou
core
liposom
use
encapsul
antigen
within
core
deliveri
form
virosom
viral
envelop
glycoprotein
incorpor
base
influenza
viru
primari
focu
virosom
studi
establish
industri
applic
human
vaccin
five
vaccin
base
virosom
clinic
trial
four
virosom
vaccin
approv
commerci
applic
variou
diseas
one
commonli
use
np
adjuv
deliveri
dna
vaccin
liposomepolycationdna
np
form
combin
cation
liposom
cation
polymercondens
dna
liposomepolycationdna
assembl
form
nanostructur
condens
dna
locat
insid
liposom
size
nm
moon
et
al
report
develop
malaria
vaccin
could
use
deliveri
polymer
plga
np
envelop
lipid
antigen
work
moon
cowork
develop
pathogenmimick
nanovaccin
candid
malari
antigen
conjug
lipid
membran
incorpor
immunostimulatori
molecul
monophosphoryl
lipid
ampla
use
elicit
immun
respons
p
vivax
sporozoit
yang
et
al
use
cancer
cell
membran
modifi
lipid
use
lipidanchor
method
coat
polymer
np
tolllik
receptor
tlr
biomimet
membran
nanocarri
report
use
anticanc
vaccin
well
deliveri
tlr
adjuv
vlp
molecul
resembl
structur
virus
without
viral
genet
materi
selfassembl
np
lack
infecti
nucleic
acid
form
selfassembl
biocompat
capsid
protein
ideal
nanovaccin
system
innat
viral
structur
interact
immun
system
without
threat
caus
infect
vlp
act
vaccin
nanos
repetit
structur
order
could
induc
immun
respons
absenc
adjuv
vlp
assembl
without
encapsul
viral
rna
henc
noninfecti
nonrepl
gene
code
viral
integras
delet
express
prevent
pack
genom
integr
host
cell
well
recombin
live
defect
viru
first
vlp
vaccin
develop
hepat
b
viru
later
commerci
vlp
vaccin
hepat
e
human
papillomaviru
use
human
sinc
vlp
obtain
varieti
virus
differ
size
rang
nm
obtain
via
differ
process
initi
approach
obtain
vlp
involv
selfassembl
capsid
protein
express
host
follow
purif
assembl
protein
avoid
contamin
adher
encapsul
howev
case
better
qualiti
low
contamin
vlp
structur
need
disassembl
reassembl
anoth
emerg
method
obtain
vlp
use
cellfre
vitro
process
wherein
first
largescal
purif
perform
prevent
contamin
assembl
vlp
structur
vitro
avoid
disassembl
cell
commerci
vlp
deriv
target
viru
selfassembl
protein
vlp
use
deliveri
vehicl
target
antigen
viru
differ
one
use
vlp
attach
vlp
surfac
surfacemodifi
vlp
pave
way
use
target
variou
diseas
vlp
could
engin
attach
addit
protein
surfac
either
fusion
protein
particl
express
multipl
antigen
turn
protect
sourc
viru
antigen
present
surfac
polysaccharid
small
organ
molecul
nonprotein
antigen
chemic
attach
vlp
surfac
form
bioconjug
particl
baculoviru
express
system
mostli
use
gener
vlp
excel
safeti
profil
baculoviru
natur
infect
human
anoth
studi
safe
effici
vlp
system
base
avian
retroviru
design
system
consid
safe
could
replic
human
cell
system
consid
safe
vlp
constitut
gag
fusion
protein
singl
vlp
could
deliv
copi
gag
fusion
protein
transduc
cell
anoth
studi
vlp
creat
deliveri
two
differ
approach
intracellular
distribut
gag
fusion
protein
modifi
surfac
vlp
receptorligandmedi
deliveri
figur
delet
express
prevent
pack
genom
integr
host
cell
well
recombin
live
defect
viru
first
vlp
vaccin
develop
hepat
b
viru
later
commerci
vlp
vaccin
hepat
e
human
papillomaviru
use
human
sinc
vlp
obtain
varieti
virus
differ
size
rang
nm
obtain
via
differ
process
initi
approach
obtain
vlp
involv
selfassembl
capsid
protein
express
host
follow
purif
assembl
protein
avoid
contamin
adher
encapsul
howev
case
better
qualiti
low
contamin
vlp
structur
need
disassembl
reassembl
anoth
emerg
method
obtain
vlp
use
cellfre
vitro
process
wherein
first
largescal
purif
perform
prevent
contamin
assembl
vlp
structur
vitro
avoid
disassembl
cell
commerci
vlp
deriv
target
viru
selfassembl
protein
vlp
use
deliveri
vehicl
target
antigen
viru
differ
one
use
vlp
attach
vlp
surfac
surfacemodifi
vlp
pave
way
use
target
variou
diseas
vlp
could
engin
attach
addit
protein
surfac
either
fusion
protein
particl
express
multipl
antigen
turn
protect
sourc
viru
antigen
present
surfac
polysaccharid
small
organ
molecul
nonprotein
antigen
chemic
attach
vlp
surfac
form
bioconjug
particl
baculoviru
express
system
mostli
use
gener
vlp
excel
safeti
profil
baculoviru
natur
infect
human
anoth
studi
safe
effici
vlp
system
base
avian
retroviru
design
system
consid
safe
could
replic
human
cell
system
consid
safe
vlp
constitut
gag
fusion
protein
singl
vlp
could
deliv
copi
gag
fusion
protein
transduc
cell
anoth
studi
vlp
creat
deliveri
two
differ
approach
intracellular
distribut
gag
fusion
protein
modifi
surfac
vlp
receptorligandmedi
deliveri
figur
selfassembl
protein
nanoparticl
np
mani
natur
occur
protein
selfassembl
form
np
high
symmetri
stabil
np
structur
organ
form
particl
rang
size
nm
selfassembl
protein
nanoparticl
np
mani
natur
occur
protein
selfassembl
form
np
high
symmetri
stabil
np
structur
organ
form
particl
rang
size
nm
np
divers
physiolog
role
select
vaccin
carrier
owe
abil
selfassembl
deploy
definit
structur
mimic
natur
microb
architectur
ferritin
protein
protect
cell
damag
caus
fenton
reaction
iron
catalyz
hydrogen
peroxid
convert
highli
toxic
hydroxyl
radic
oxid
condit
harm
reactiv
oxygen
speci
produc
free
fe
ii
damag
cellular
machineri
ferritin
hollow
structur
abil
store
iron
within
hollow
caviti
thu
act
storag
system
iron
ferritin
selfassembl
spheric
nanostructur
use
fuse
influenza
viru
haemagglutinin
ha
genet
recombin
protein
spontan
assembl
particl
octahedr
symmetri
reform
eight
trimer
ha
spike
elicit
stronger
immun
respons
compar
inactiv
trival
influenza
viru
anoth
type
selfassembl
protein
major
vault
protein
mvp
champion
et
al
report
unit
mvp
selfassembl
form
barrelshap
vault
np
length
nm
width
nm
mention
genet
fuse
antigen
minim
interact
could
load
onto
vault
np
selfassembl
mix
mvp
work
encapsul
immunogen
protein
term
major
outer
membran
protein
chlamydia
muridarum
hollow
vault
nanocapsul
hollow
vault
nanocapsul
modifi
bind
igg
enhanc
immun
respons
induc
protect
immun
distant
mucos
surfac
wahom
et
al
report
anoth
selfassembl
protein
np
adjuvantfre
immunogen
obtain
selfassembl
monomer
chain
order
oligomer
form
antigenpres
system
could
suitabl
vaccin
selfassembl
protein
np
form
incorpor
membraneproxim
extern
region
mper
identifi
target
wide
rang
neutral
antibodi
ntermin
pentam
produc
state
epitop
without
caus
structur
chang
epitop
selfassembl
np
show
enhanc
membraneproxim
regionspecif
titer
owe
presenc
repetit
antigen
display
mper
even
without
adjuv
thu
result
format
adjuvantfre
immunogen
potenti
hiv
vaccin
discuss
previou
section
cell
membran
decor
np
emerg
promis
method
camouflag
form
thin
layer
cell
membran
coat
np
camouflag
np
inherit
properti
sourc
cell
depend
sourc
cell
use
exampl
rbc
employ
sourc
membran
membraneco
np
found
possess
immun
evas
prolong
circul
biomimet
np
attain
cell
mimick
properti
transfer
sourc
cell
membran
protein
onto
surfac
np
function
approach
regard
highli
versatil
allow
deliveri
wide
rang
cargo
encompass
variou
innercor
materi
target
drug
deliveri
employ
inher
adher
capabl
sourc
cell
exampl
np
camouflag
layer
cancer
cell
membran
show
inherit
homotyp
adhes
properti
intrins
capac
bind
sourc
cell
addit
np
camouflag
platelet
membran
display
abil
mimic
platelet
bind
pathogen
methicillinresist
staphylococcu
aureu
target
antibiot
deliveri
meanwhil
platelet
help
recogn
tumor
cell
includ
circul
tumor
cell
ligand
bind
interact
platelet
membranecamouflag
np
primarili
formul
sitespecif
deliveri
anticanc
drug
persuas
applic
inspir
develop
cell
membranecamouflag
np
target
antibiot
deliveri
h
pylori
infect
angsantikul
et
al
report
nanotherapeut
obtain
coat
antibioticload
poli
lacticcoglycol
acid
plga
np
gastric
epitheli
cell
membran
h
pylori
infect
studi
found
gastric
epitheli
cellular
membraneco
np
surfac
antigen
sourc
cell
exhibit
inher
adhes
toward
h
pylori
bacteria
use
bacteri
membran
vaccin
materi
gain
consider
interest
stimul
innat
immun
promot
adapt
immun
respons
exhibit
differ
pathogen
associatedmolecular
pattern
pamp
larg
number
immunogen
antigen
adjuv
properti
camouflag
np
cover
bacteri
membran
result
preserv
bacteri
characterist
thu
help
mimick
natur
antigen
present
bacteria
immun
system
gao
et
al
report
bacteri
membran
coat
np
antibacteri
therapi
gold
np
coat
bacteri
outer
vesicl
studi
chose
e
coli
bacteria
obtain
outer
membran
coat
gold
np
nm
size
found
could
induc
rapid
activ
dc
matur
lymph
node
vaccin
np
produc
longlast
robust
antibodi
respons
exosom
nanos
membraneenclos
extracellular
vesicl
origin
inner
endosom
membran
vesicl
compos
lipophil
bilay
protein
genet
materi
micro
rna
mrna
dna
exosom
mediat
cell
induc
immun
respons
activ
natur
killer
nk
cell
dendrit
cell
dc
lymphocyt
cell
variou
physiolog
stimuli
inflamm
oxid
stress
cell
growth
affect
secret
exosom
cell
use
promin
diagnosi
marker
exosom
act
vaccin
infect
use
carrier
pathogen
antigen
modul
immun
respons
recruit
monocyt
macrophag
nk
cell
cell
infecti
agent
mention
earlier
section
biomimet
immunomodulatori
nanovaccin
compos
biomimet
np
cargo
use
section
differ
type
cargo
use
nanovaccin
explain
adjuv
ingredi
use
vaccin
enabl
bodi
produc
stronger
immun
respons
help
vaccin
work
better
differ
mechan
adjuv
elicit
immun
respons
follow
prolong
releas
antigen
site
inject
cytokin
chemokin
level
get
upregul
recruit
cell
inject
site
antigen
uptak
present
antigenpres
cell
increas
apc
activ
matur
result
migrat
drain
lymph
node
inflammasom
activ
gener
adjuv
classifi
base
mechan
action
physicochem
properti
origin
adjuv
classifi
deliveri
system
immun
potenti
depend
action
mechan
tabl
describ
partial
list
adjuv
use
abovement
three
categori
champion
et
al
report
vault
np
vaccin
induc
protect
immun
distant
mucos
surfac
vault
np
contain
immunogen
protein
henc
consid
adjuv
anoth
studi
riitho
et
al
formul
biomimet
vaccin
encapsul
viral
protein
insid
polymer
shell
wherein
viral
protein
known
effect
crosspresent
mhc
class
polymer
np
adjuv
polyinosin
polycytidyl
acid
poli
c
load
viral
protein
act
antigen
nanovaccin
exhibit
signific
virusneutr
activ
effect
infect
caus
bovin
viru
diarrheaviru
wang
et
al
report
use
dualfunct
nanomodul
enhanc
cpg
mediat
cancer
therapi
work
synthes
manganes
oxid
nanosheet
conjug
anticanc
drug
doxorubicin
dox
cpgsilver
nanoclust
adjuv
yang
et
al
report
use
lipid
dspepegmannos
modifi
cancer
cell
membran
coat
onto
polymer
np
load
adjuv
tlr
anticanc
effect
recent
le
et
al
suggest
situ
nanoadjuv
tumor
vaccin
prevent
longterm
recurr
tumor
studi
polydopamin
np
load
imiquimod
np
surfac
modifi
program
deathligand
antibodi
codeliveri
antigen
adjuv
antigenpres
cell
nanoadjuv
antibodi
could
block
immun
checkpoint
tumor
expect
combin
phototherm
immunotherapi
effect
moon
et
al
report
develop
recombin
antigen
deriv
circumsporozoit
protein
predomin
membran
protein
sporozoit
initi
work
state
recombin
antigen
mix
convent
antigen
could
elicit
antigenspecif
antibodi
respons
use
lipid
envelop
polymer
np
conjug
malari
antigen
lipid
membran
immunostimulatori
molecul
monophosphoryl
lipid
incorpor
lipid
membran
result
pathogenmimick
np
vaccin
anoth
studi
suggest
antigenload
np
display
monophosphoryl
lipid
mpla
encapsul
adjuv
cpg
motif
model
antigen
ovalbumin
could
act
effici
bacteri
vaccin
studi
cpg
potenc
found
enhanc
encapsul
insid
np
turn
highlight
import
biomimet
present
pathogenassoci
molecular
pattern
mpla
cpg
proinflammatori
antigenspecif
helper
th
cellular
antibodymedi
immun
respons
significantli
increas
sahu
et
al
report
use
monophosphoryl
lipid
mpla
np
load
hepat
b
surfac
antigen
hbsag
deliveri
colon
provid
prolong
immun
hepat
b
infect
studi
mpla
adjuv
activ
tolllik
receptor
type
tlr
hb
ag
act
antigen
deliv
thu
enabl
simultan
deliveri
adjuv
antigen
insid
colon
result
indic
effect
gener
humor
cellular
immun
respons
stimul
interferon
gene
sting
promin
agonist
stimul
cyclic
dinucleotid
cdn
activ
pathway
secret
variou
proinflammatori
cytokin
jack
hu
et
al
develop
ph
sensit
capsidlik
hollow
polymer
nanoparticl
load
sting
agonist
cyclic
diguanyl
monophosph
cdgmp
middl
east
respiratori
syndrom
coronaviru
merscov
vaccin
deliveri
sting
agonist
merscov
receptor
bind
domain
antigen
surfac
nanoparticl
mimick
viruslik
nanoparticl
induc
type
immun
respons
promin
vaccin
infect
toxoid
chemic
physic
modifi
toxin
longer
harm
retain
immunogen
wang
et
al
develop
nanotoxoid
consist
rbc
membraneco
polymer
np
membran
coat
act
substrat
poreform
staphylococc
hla
nanotoxoid
therebi
effect
trigger
format
germin
center
recent
wei
et
al
report
macrophagemembraneco
nanotoxoid
pathogen
pseudomona
aeruginosa
alreadi
report
previous
alveolar
macrophag
cation
protein
bind
outer
membran
bacteria
pseudomona
aeruginosa
flagella
also
get
involv
phagocytosi
biomimet
nanovaccin
ideal
vaccin
candid
uniqu
physicochem
paramet
size
shape
biomimick
properti
featur
make
versatil
deliveri
system
deliveri
antigen
adjuv
main
advantag
nanovaccin
abil
incorpor
antigen
adjuv
within
singl
particl
produc
maximum
stimul
biomimick
properti
nanovaccin
reduc
interact
re
cell
provid
longer
circul
prevent
burst
releas
adjuv
nanoformul
synthesi
method
choic
materi
use
np
formul
make
nanovaccin
flexibl
incorpor
differ
molecul
protein
polysaccharid
lipid
polym
nucleic
acid
np
local
enhanc
modifi
np
surfac
ligand
specif
immun
cell
receptor
moreov
antigen
adjuv
load
np
either
individu
combinatori
approach
protect
molecul
integr
differ
enzym
nucleas
phosphatas
besid
advantag
np
formul
also
prevent
adjuv
degrad
protect
bodi
potenti
system
toxic
caus
prematur
releas
adjuv
enhanc
immun
respons
extend
cargo
releas
anoth
advantag
biomimet
nanovaccin
abil
target
immun
cell
nanos
nanovaccin
drain
lymphat
system
allow
effici
deliveri
lymph
node
immun
cell
densiti
high
select
biomimet
np
play
essenti
role
improv
vaccin
effici
biomimet
nanovaccin
help
shield
np
recogn
mononuclear
phagocyt
system
help
immun
escap
shield
np
protect
cargo
prematur
releas
modif
surfac
nanovaccin
certain
receptor
enhanc
target
abil
well
help
enhanc
accumul
biomimet
nanovaccin
develop
simul
synthet
np
biolog
deriv
materi
combin
synthet
biolog
properti
key
recent
wei
et
al
report
macrophagemembraneco
nanotoxoid
pathogen
pseudomona
aeruginosa
alreadi
report
previous
alveolar
macrophag
cation
protein
bind
outer
membran
bacteria
pseudomona
aeruginosa
flagella
also
get
involv
phagocytosi
biomimet
nanovaccin
ideal
vaccin
candid
uniqu
physicochem
paramet
size
shape
biomimick
properti
featur
make
versatil
deliveri
system
deliveri
antigen
adjuv
main
advantag
nanovaccin
abil
incorpor
antigen
adjuv
within
singl
particl
produc
maximum
stimul
biomimick
properti
nanovaccin
reduc
interact
re
cell
provid
longer
circul
prevent
burst
releas
adjuv
nanoformul
synthesi
method
choic
materi
use
np
formul
make
nanovaccin
flexibl
incorpor
differ
molecul
protein
polysaccharid
lipid
polym
nucleic
acid
np
local
enhanc
modifi
np
surfac
ligand
specif
immun
cell
receptor
moreov
antigen
adjuv
load
np
either
individu
combinatori
approach
protect
molecul
integr
differ
enzym
nucleas
phosphatas
besid
advantag
np
formul
also
prevent
adjuv
degrad
protect
bodi
potenti
system
toxic
caus
prematur
releas
adjuv
enhanc
immun
respons
extend
cargo
releas
anoth
advantag
biomimet
nanovaccin
abil
target
immun
cell
nanos
nanovaccin
drain
lymphat
system
allow
effici
deliveri
lymph
node
immun
cell
densiti
high
select
biomimet
np
play
essenti
role
improv
vaccin
effici
biomimet
nanovaccin
help
shield
np
recogn
mononuclear
phagocyt
system
help
immun
escap
shield
np
protect
cargo
prematur
releas
modif
surfac
nanovaccin
certain
receptor
enhanc
target
abil
well
help
enhanc
accumul
biomimet
nanovaccin
develop
simul
synthet
np
biolog
deriv
materi
combin
synthet
biolog
properti
key
factor
improv
therapeut
efficaci
treatment
biomimet
nanovaccin
come
sever
varieti
liposom
protein
cellmembraneco
np
vlp
modifi
antigen
adjuv
shown
figur
stimul
immun
respons
bodi
due
presenc
variou
cell
membran
protein
antibodi
surfac
nanovaccin
possibl
quickli
evad
immun
system
biomimet
surfac
engin
unusu
approach
toward
develop
current
therapeut
action
factor
improv
therapeut
efficaci
treatment
biomimet
nanovaccin
come
sever
varieti
liposom
protein
cellmembraneco
np
vlp
modifi
antigen
adjuv
shown
figur
stimul
immun
respons
bodi
due
presenc
variou
cell
membran
protein
antibodi
surfac
nanovaccin
possibl
quickli
evad
immun
system
biomimet
surfac
engin
unusu
approach
toward
develop
current
therapeut
action
bacteri
infect
mark
lifethreaten
diseas
caus
pathogen
bacteria
counter
infecti
diseas
antibiot
introduc
th
centuri
role
antibiot
interfer
growth
cycl
bacteria
suppress
reproduct
rate
antibiot
disinfect
surfac
elimin
bacteria
bodi
overexposur
antibiot
extend
period
lower
effect
infect
np
make
direct
contact
bacteria
cell
wall
without
cell
penetr
show
np
efficaci
altern
antibiot
resist
biomimet
np
investig
altern
drug
deliveri
carrier
due
remark
blood
circul
time
biocompat
target
bacteri
membran
stimul
innat
adapt
immun
insid
human
bodi
due
presenc
immunogen
adjuv
antigen
express
numer
pathogen
associ
molecular
pattern
pamp
therefor
bacterialmembraneco
np
consid
potenti
vaccin
antibacteri
bacteri
infect
mark
lifethreaten
diseas
caus
pathogen
bacteria
counter
infecti
diseas
antibiot
introduc
centuri
role
antibiot
interfer
growth
cycl
bacteria
suppress
reproduct
rate
antibiot
disinfect
surfac
elimin
bacteria
bodi
overexposur
antibiot
extend
period
lower
effect
infect
np
make
direct
contact
bacteria
cell
wall
without
cell
penetr
show
np
efficaci
altern
antibiot
resist
biomimet
np
investig
altern
drug
deliveri
carrier
due
remark
blood
circul
time
biocompat
target
bacteri
membran
stimul
innat
adapt
immun
insid
human
bodi
due
presenc
immunogen
adjuv
antigen
express
numer
pathogen
associ
molecular
pattern
pamp
therefor
bacterialmembraneco
np
consid
potenti
vaccin
antibacteri
therapi
weiwei
et
al
report
antibacteri
vaccin
show
effect
immun
respons
pathogen
neisseria
meningitid
treatment
function
gold
np
size
nm
outer
vesicl
bacteri
membran
extract
e
coli
bmaunp
show
remark
serum
stabil
shown
figur
rapid
dc
matur
lymph
node
strong
antibodi
respons
induc
bmaunp
vaccin
bmaunp
produc
bacterium
specif
tcell
respons
higher
product
interferongamma
interleukin
respons
tcell
respons
bacteri
infect
pathogen
neisseria
meningitid
treatment
function
gold
np
size
nm
outer
vesicl
bacteri
membran
extract
e
coli
bmaunp
show
remark
serum
stabil
shown
figur
rapid
dc
matur
lymph
node
strong
antibodi
respons
induc
bmaunp
vaccin
bmaunp
produc
bacterium
specif
tcell
respons
higher
product
interferongamma
interleukin
respons
tcell
respons
bacteri
infect
wang
et
al
report
antivirul
biomimet
nanovaccin
assembl
cell
membran
coat
methicillinresist
staphylococcu
aureu
mrsa
skin
infect
rbcmembran
coat
plga
np
act
natur
substrat
poreform
toxin
entrap
poreform
staphylococc
hla
onto
surfac
reduc
mrsa
infect
vlp
vaccin
develop
hepat
b
viru
core
protein
combin
mycobacterium
tuberculosi
antigen
cultur
filtrat
protein
tuberculosi
tb
cfp
tcell
antigen
induc
vigor
ctl
activ
secret
report
signific
tb
vaccin
biomimet
vaccin
express
antigenspecif
immun
consid
effect
tb
vaccin
endolysin
bacteriophagesecret
enzym
respons
degrad
peptidoglycan
present
bacteri
cell
wall
liposom
deliveri
endolysin
signific
way
treat
gramposit
bacteria
overcom
drawback
nativ
endolysin
unabl
penetr
outer
membran
bacteria
rbc
membraneco
biomimet
supramolecular
gelatin
nanoparticl
load
vancomycin
vansgnp
rbc
develop
ondemand
deliveri
antibiot
rbc
membran
coat
provid
immun
evas
trigger
accumul
nanovaccin
infect
site
due
rbc
membran
coat
surfac
vansgnp
rbc
nanovaccin
adsorb
bacteri
endotoxin
reduc
endotoxinrel
sideeffect
patient
larg
number
gelatinas
secret
bacteria
infecti
microenviron
nanovaccin
respons
hydrolyz
gelatin
trigger
load
drug
vancomycin
reduc
bacteri
infect
immuneevas
properti
vansgnp
rbc
examin
label
np
incub
raw
macrophag
cell
result
show
vansgnp
rbc
less
macrophag
uptak
compar
vansgnp
indic
circumvent
vansgnp
rbc
np
immun
cell
highli
activ
antiretrovir
therapi
haart
promin
strategi
treatment
wang
et
al
report
antivirul
biomimet
nanovaccin
assembl
cell
membran
coat
methicillinresist
staphylococcu
aureu
mrsa
skin
infect
rbcmembran
coat
plga
np
act
natur
substrat
poreform
toxin
entrap
poreform
staphylococc
hla
onto
surfac
reduc
mrsa
infect
vlp
vaccin
develop
hepat
b
viru
core
protein
combin
mycobacterium
tuberculosi
antigen
cultur
filtrat
protein
tuberculosi
tb
cfp
tcell
antigen
induc
vigor
ctl
activ
secret
report
signific
tb
vaccin
biomimet
vaccin
express
antigenspecif
immun
consid
effect
tb
vaccin
endolysin
bacteriophagesecret
enzym
respons
degrad
peptidoglycan
present
bacteri
cell
wall
liposom
deliveri
endolysin
signific
way
treat
gramposit
bacteria
overcom
drawback
nativ
endolysin
unabl
penetr
outer
membran
bacteria
rbc
membraneco
biomimet
supramolecular
gelatin
nanoparticl
load
vancomycin
vansgnp
rbc
develop
ondemand
deliveri
antibiot
rbc
membran
coat
provid
immun
evas
trigger
accumul
nanovaccin
infect
site
due
rbc
membran
coat
surfac
vansgnp
rbc
nanovaccin
adsorb
bacteri
endotoxin
reduc
endotoxinrel
sideeffect
patient
larg
number
gelatinas
secret
bacteria
infecti
microenviron
nanovaccin
respons
hydrolyz
gelatin
trigger
load
drug
vancomycin
reduc
bacteri
infect
immuneevas
properti
vansgnp
rbc
examin
label
np
incub
raw
macrophag
cell
result
show
vansgnp
rbc
less
macrophag
uptak
compar
vansgnp
indic
circumvent
vansgnp
rbc
np
immun
cell
highli
activ
antiretrovir
therapi
haart
promin
strategi
treatment
acquir
immunodefici
syndrom
aid
caus
human
immunodefici
viru
hiv
nanovaccin
nanocapsul
nanocryst
lipid
np
nanocarri
liposom
micel
recent
investig
antihiv
therapi
although
mani
antiretrovir
drug
avail
treatment
none
erad
viral
reservoir
engin
biomimet
nanovaccin
advers
properti
modul
immun
system
viral
infect
show
high
encapsul
effici
antiretrovir
drug
cytokin
enzym
sitespecif
drug
releas
liposom
endocytos
mononuclear
phagocyt
system
cell
mp
reach
hivinfect
reservoir
liposom
deliveri
antihiv
vaccin
investig
induc
antibodi
cellular
immun
respons
year
ago
formul
liposom
vaccin
immun
stimul
recombin
hiv
envelop
protein
antigen
show
strong
antibodi
respons
compar
liposom
deliveri
liposom
alon
pathogenfre
mice
vaccin
antibodi
product
ctl
activ
significantli
increas
hanson
et
al
investig
liposom
deliveri
membraneproxim
extern
region
mper
suitabl
antigen
monophosphoryl
lipida
mpla
stimul
interferon
gene
sting
agonist
cyclicdigmp
cdgmp
activ
hiv
vaccin
administr
liposom
vaccin
mper
molecular
adjuv
mpla
cdgmp
achiev
signific
humor
respons
well
tcell
respons
andersson
et
al
develop
hiv
vlp
compos
hiv
env
antigen
hiv
bal
viral
surfac
glycoprotein
target
tlr
ligand
hiv
vlp
vaccin
modul
immun
system
maintain
germin
center
bcell
hypermut
preserv
germin
center
result
secret
high
hiv
neutral
antibodi
vlp
like
nanovaccin
compos
antigen
differ
tlr
ligand
dsrna
mpla
resiquimod
acceler
immunogen
mice
combin
nanovaccin
induc
like
cytokin
prolong
lymph
node
germin
center
follicular
cell
antibodi
product
intranas
immun
hiv
vlp
nanovaccin
week
reduc
envspecif
titer
howev
titer
well
maintain
studi
main
factor
gener
neutral
antibodi
hiv
combin
antigen
adjuv
vlp
show
robust
immun
respons
wellmaintain
germin
center
vlp
encod
adenoviru
prime
immunogen
effect
strategi
toward
hiv
vaccin
envelop
glycoprotein
env
antibodyinduc
prophylact
drug
present
particl
vlp
encod
dock
consensu
env
antigen
produc
antibodi
respons
releas
neutral
antibodi
hiv
ectodomain
protein
investig
recent
altern
env
target
induct
neutral
antibodi
hiv
deliveri
lipid
nanocapsul
modifi
trimer
surfac
promot
strong
antibodi
respons
timerantibodi
bind
composit
nanocapsul
induc
remark
humor
respons
day
env
immunogen
compar
solubl
trimer
adjuv
protein
oilinwat
emuls
cellmembraneco
np
also
emerg
effect
platform
treat
hiv
infect
hiv
infect
explicitli
target
tcell
reduc
immun
cell
viral
kill
uninfect
cell
lead
apoptosi
wei
et
al
develop
tcell
membraneco
biomimet
nanovaccin
neutral
viral
infect
shown
figur
viral
fusion
viru
immun
cell
start
interact
cd
receptor
glycoprotein
cc
chemokin
receptor
cxc
chemokin
receptor
type
tcell
modifi
plga
nanovaccin
mimick
parent
tcell
induc
specif
bind
hiv
biomimet
agent
divert
viral
attack
deplet
viral
infect
malaria
ubiquit
parasit
diseas
found
worldwid
caus
protozoan
parasit
current
treatment
malaria
involv
oral
administr
tradit
antimalaria
drug
chloroquin
pyrimethamin
artesun
sulfadoxin
potenc
drug
diminish
drug
resist
abil
parasit
downsid
current
treatment
malaria
includ
low
stabil
stomach
higher
side
effect
low
halflif
insid
bodi
nanovaccin
best
altern
combat
parasit
diseas
nanocarri
carri
activ
drug
specif
site
minim
loss
side
effect
advers
therapeut
effect
biomimet
nanocarri
liposom
protein
highli
biocompat
promis
drug
deliveri
applic
malaria
vaccin
less
resist
recombin
antigen
requir
repeat
reboost
liposom
wellknown
drug
carrier
deliv
drug
within
host
without
degrad
surfac
modif
liposom
target
ligand
antibodi
precis
bind
infect
cell
facilit
sitespecif
drug
deliveri
marqu
et
al
report
heparinco
liposom
load
primaquin
advers
antimalari
activ
due
higher
bind
affin
heparin
toward
heparinbind
protein
infect
erythrocyt
cell
membran
surfac
deliv
drug
infect
site
immunoliposom
ilp
liposom
modifi
target
immun
system
recent
investig
antimalari
activ
target
plasmodiuminfect
red
blood
cell
prbc
liposom
modifi
glycosaminoglycan
chondroitin
heparin
substitut
deliveri
primaquin
shown
addit
effect
compar
control
plasmodium
falciparum
erythrocyt
membran
protein
primari
receptor
sulfat
parasitemedi
antigen
present
endothelium
postcapillari
venul
enhanc
adhes
liposom
toward
prbc
rajeev
et
al
report
antimalaria
vaccin
liposom
deliveri
merozoit
surfac
protein
present
surfac
plasmodium
falciparum
transcutan
inject
antigen
acceler
immun
respons
activ
epiderm
antigenpres
cell
liposom
deliveri
membran
antigen
induc
strong
humor
cellmedi
immun
respons
labdhi
et
al
develop
selfassembl
protein
nanovaccin
deliveri
malaria
ubiquit
parasit
diseas
found
worldwid
caus
protozoan
parasit
current
treatment
malaria
involv
oral
administr
tradit
antimalaria
drug
chloroquin
pyrimethamin
artesun
sulfadoxin
potenc
drug
diminish
drug
resist
abil
parasit
downsid
current
treatment
malaria
includ
low
stabil
stomach
higher
side
effect
low
halflif
insid
bodi
nanovaccin
best
altern
combat
parasit
diseas
nanocarri
carri
activ
drug
specif
site
minim
loss
side
effect
advers
therapeut
effect
biomimet
nanocarri
liposom
protein
highli
biocompat
promis
drug
deliveri
applic
malaria
vaccin
less
resist
recombin
antigen
requir
repeat
reboost
liposom
wellknown
drug
carrier
deliv
drug
within
host
without
degrad
surfac
modif
liposom
target
ligand
antibodi
precis
bind
infect
cell
facilit
sitespecif
drug
deliveri
marqu
et
al
report
heparinco
liposom
load
primaquin
advers
antimalari
activ
due
higher
bind
affin
heparin
toward
heparinbind
protein
infect
erythrocyt
cell
membran
surfac
deliv
drug
infect
site
immunoliposom
ilp
liposom
modifi
target
immun
system
recent
investig
antimalari
activ
target
plasmodiuminfect
red
blood
cell
prbc
liposom
modifi
glycosaminoglycan
chondroitin
heparin
substitut
deliveri
primaquin
shown
addit
effect
compar
control
plasmodium
falciparum
erythrocyt
membran
protein
primari
receptor
sulfat
parasitemedi
antigen
present
endothelium
postcapillari
venul
enhanc
adhes
liposom
toward
prbc
rajeev
et
al
report
antimalaria
vaccin
liposom
deliveri
merozoit
surfac
protein
present
surfac
plasmodium
falciparum
transcutan
inject
antigen
acceler
immun
respons
activ
epiderm
antigenpres
cell
liposom
deliveri
membran
antigen
induc
strong
humor
cellmedi
immun
respons
labdhi
et
al
develop
selfassembl
protein
nanovaccin
deliveri
adjuvantbas
liposom
target
plasmodium
falciparum
selfassembl
protein
np
contain
monom
protein
chain
compris
p
falciparum
circumsporozoit
protein
pf
csp
cd
cd
h
epitop
induc
immun
respons
adjuvantaug
alhydrogel
liposom
deliveri
selfassembl
protein
nanovaccin
target
nativ
pf
csp
stimul
immun
respons
mice
gain
complet
protect
malaria
deliveri
two
antimalari
drug
lipophil
aminoquinolin
amino
alcohol
deriv
encapsul
ilp
encapsul
effici
citrat
buffer
ph
gradient
method
ilp
perform
vivo
rbc
target
show
higher
retent
time
reduc
malaria
parasit
densiti
blood
compar
nontarget
deliveri
rt
vaccin
develop
glaxosmithklin
gsk
first
malaria
vaccin
clinic
trial
rt
singl
polypeptid
specif
toward
plasmodium
falciparum
fuse
polypeptid
produc
vlp
rt
antigen
effect
formul
reduc
malaria
infect
children
rt
vaccin
circumsporozoit
protein
csp
base
vlp
csphepat
b
surfac
antigen
hbsag
fusion
protein
target
preerythrocyt
stage
plasmodium
falciparum
infect
kathrin
et
al
develop
immunogen
cspbase
particl
vaccin
compar
rt
name
compris
singl
csphepat
b
surfac
antigen
hbsag
fusion
protein
higher
proport
csp
rt
induc
robust
immun
respons
plasmodium
falciparum
infect
low
dosag
deliveri
adjuv
matrixm
achiev
strong
humor
cellular
immun
respons
sporozoit
challeng
balbc
mice
combin
thrombospondin
relat
adhes
protein
trap
induc
high
level
trapspecif
tcell
current
clinic
trial
develop
biomimet
np
chemic
structur
modif
mimic
biolog
environ
establish
approach
cancer
therapi
nanovaccin
novel
platform
deliveri
adjuv
antigen
gener
strong
antitumor
respons
modul
immun
system
variou
type
nanovaccin
liposom
protein
np
cellmembraneco
nanomicel
recent
develop
success
anticanc
therapi
modif
surfac
function
biomimet
nanovaccin
acceler
therapeut
activ
high
cellular
uptak
prolong
circul
sitespecif
accumul
stimulirespons
drug
releas
phospholipid
primari
element
liposom
formul
mimic
biolog
membran
formul
ilp
introduc
specif
antibodi
antigen
onto
surfac
induc
activ
target
immun
modul
antigen
present
liposom
induc
immunogen
insid
bodi
encapsul
surfac
modifi
antigen
alter
tcell
respons
stimul
tcell
fight
tumor
phosphatidylserin
conjug
liposom
effect
vaccin
significantli
captur
antigenpres
cell
respons
h
cell
prolifer
polyinosin
polycytidyl
acid
poli
c
mediat
cation
liposom
report
adequ
vaccin
deliveri
natur
epitop
herneuderiv
peptid
enhanc
antitumor
immun
poli
c
tlr
agonist
display
strong
immun
respons
trigger
apoptosi
liposom
vaccin
peptid
poli
c
significantli
induc
antitumor
immun
respons
releas
higher
number
tcell
interferongamma
compar
singl
vaccin
either
peptid
poli
c
liposom
inject
poli
c
induc
strong
cytotox
lymphocyt
ctl
respons
inhibit
tumor
growth
compar
control
peptid
conjug
liposom
deliveri
monophosphoryl
lipid
mpla
tlr
agonist
enhanc
secret
ctl
respons
induc
tcell
liposom
vaccin
mpl
achiev
signific
tumor
inhibit
longer
surviv
time
cellmembraneco
np
type
biomimet
nanovaccin
use
anticanc
therapeut
agent
presenc
sever
function
molecul
cell
surfac
cell
membran
coat
nanovaccin
act
nativ
antigen
immun
cell
tumor
cell
membran
coat
hydrophob
core
np
demonstr
selfrecogn
properti
target
rbccoat
np
could
evad
immun
system
due
presenc
variou
immunomodulatori
marker
membran
surfac
prolong
circul
longer
time
thu
enhanc
therapeut
activ
mushi
et
al
develop
camouflag
nanocarri
coat
hela
human
cervix
carcinoma
cellular
membran
onto
nanocarri
nanocarri
compos
doxorubicin
sirna
load
plga
np
target
cancer
cell
hybrid
cancer
cell
rbc
membran
superior
approach
deliveri
therapeut
activ
molecul
cancer
therapi
cancer
cell
membran
help
homotyp
target
selfrecognit
rbc
membran
prolong
blood
circul
evad
immun
system
bodi
surfac
protein
cancer
cell
membran
act
tumor
antigen
trigger
immun
respons
yang
et
al
report
cancer
cell
membraneco
plga
np
load
agonist
imiquimod
modifi
mannos
surfac
lipid
anchor
method
figur
mannos
modif
surfac
nanovaccin
trigger
antigenpres
cell
uptak
lymph
node
migrat
higher
dc
matur
cancer
cell
membran
coat
perform
target
moieti
cancerspecif
antigen
immun
modulatori
agent
imiquimod
stimul
product
cytotox
tcell
kill
cancer
cell
combin
biomimet
vaccin
act
anticanc
vaccin
inhibit
cancer
cell
progress
compar
control
melanoma
cancer
cellmembraneco
plga
np
load
cpg
oligodeoxynucleotid
augment
antitumor
immun
could
use
antigenadjuv
vaccin
cancer
cell
membran
act
tumor
antigen
enhanc
immun
respons
biomimet
nanovaccin
trigger
antigenpres
cell
matur
proinflammatori
cytokin
ie
modul
immun
respons
cancer
cell
cell
tumor
cell
membran
coat
hydrophob
core
np
demonstr
selfrecogn
properti
target
rbccoat
np
could
evad
immun
system
due
presenc
variou
immunomodulatori
marker
membran
surfac
prolong
circul
longer
time
thu
enhanc
therapeut
activ
mushi
et
al
develop
camouflag
nanocarri
coat
hela
human
cervix
carcinoma
cellular
membran
onto
nanocarri
nanocarri
compos
doxorubicin
sirna
load
plga
np
target
cancer
cell
hybrid
cancer
cell
rbc
membran
superior
approach
deliveri
therapeut
activ
molecul
cancer
therapi
cancer
cell
membran
help
homotyp
target
selfrecognit
rbc
membran
prolong
blood
circul
evad
immun
system
bodi
surfac
protein
cancer
cell
membran
act
tumor
antigen
trigger
immun
respons
yang
et
al
report
cancer
cell
membraneco
plga
np
load
agonist
imiquimod
modifi
mannos
surfac
lipid
anchor
method
figur
mannos
modif
surfac
nanovaccin
trigger
antigenpres
cell
uptak
lymph
node
migrat
higher
dc
matur
cancer
cell
membran
coat
perform
target
moieti
cancerspecif
antigen
immun
modulatori
agent
imiquimod
stimul
product
cytotox
tcell
kill
cancer
cell
combin
biomimet
vaccin
act
anticanc
vaccin
inhibit
cancer
cell
progress
compar
control
melanoma
cancer
cellmembraneco
plga
np
load
cpg
oligodeoxynucleotid
augment
antitumor
immun
could
use
antigenadjuv
vaccin
cancer
cell
membran
act
tumor
antigen
enhanc
immun
respons
biomimet
nanovaccin
trigger
antigenpres
cell
matur
proinflammatori
cytokin
ie
modul
immun
respons
cancer
cell
variou
type
target
peptid
nucleic
acid
protein
introduc
formul
biomimet
nanovaccin
activ
immun
system
cpg
oligonucleotid
act
tlr
adjuv
recognit
endosom
boost
immun
activ
regulatori
tcell
insid
cancer
patient
antibodi
found
effect
target
variou
type
target
peptid
nucleic
acid
protein
introduc
formul
biomimet
nanovaccin
activ
immun
system
cpg
oligonucleotid
act
tlr
adjuv
recognit
endosom
boost
immun
activ
regulatori
tcell
insid
cancer
patient
antibodi
found
effect
target
specif
antigen
overexpress
receptor
cancer
cell
enhanc
anticanc
therapi
antibodi
inhibit
pathway
block
convers
cytotox
tcell
regulatori
tcell
gasgener
liposom
load
sodium
bicarbon
nahco
caus
cell
death
releas
high
amount
tumorassoci
antigen
taa
combin
treatment
gasgener
liposom
anti
remark
enhanc
recruit
immun
cell
ctl
respons
along
reduct
regulatori
tcell
compar
singl
treatment
either
anti
liposom
vlp
develop
use
noninfecti
viral
protein
capsid
target
therapeut
agent
vlp
act
pathogenassoci
molecular
parent
pamp
induc
immun
stimul
cancer
lizott
et
al
report
selfassembl
vlp
cowpea
mosaic
viru
serv
effect
vaccin
delay
tumor
growth
melanoma
mice
model
vlp
obtain
durabl
longlast
humor
immun
respons
easili
adapt
toward
pathogen
threat
patel
et
al
report
influenza
vlp
modifi
breast
cancer
human
epiderm
growth
factor
receptor
antigen
potenti
therapeut
vaccin
express
tumor
vlp
immun
antigen
enhanc
type
antibodi
respons
inhibit
tumor
growth
vlp
deriv
cowpea
mosaic
viru
potent
vaccin
mous
ovarian
cancer
induc
intratumor
cytokin
respons
upregul
downregul
repolar
tumorassoci
macrophag
neutrophil
situ
vaccin
vlp
significantli
enhanc
tumorspecif
tcell
respons
aggress
ovarian
tumor
melittin
linear
cytosol
peptid
secret
honey
bee
venom
inject
anim
bodi
caus
pain
sensat
owe
pore
format
epitheli
cell
cation
peptid
respons
cell
membran
lysi
caus
high
interact
neg
charg
phospholipid
inhibit
ion
transport
cell
current
strategi
fight
melittin
base
toxoid
vaccin
elimin
toxic
poreform
toxin
preserv
immun
epitop
consider
challeng
research
biomimet
nanovaccin
best
altern
deliveri
toxin
suitabl
toxoid
vaccin
sinc
maintain
antigen
activ
nativ
toxin
induc
immun
respons
bodi
rbc
membraneco
np
use
suitabl
carrier
anchor
staphylococc
ahemolysin
hla
model
toxin
toward
nondisrupt
nanotoxoid
format
nanotoxoid
vaccin
stimul
host
bodi
immun
elimin
toxin
antigenpres
mechan
kang
et
al
report
nanotoxoid
format
method
might
promis
approach
poreform
toxin
pft
vaccin
synthet
pda
np
effici
neutral
melittin
reduc
toxic
melittin
interact
polydiacetylen
pda
np
melittin
mediat
hydrophob
electrostat
interact
melittinload
pda
np
use
nanotoxoid
vaccin
enhanc
immun
activ
melittin
pdamelittin
demonstr
cell
viabil
dc
wherea
free
melittin
show
cell
apoptosi
biomimet
nanovaccin
maintain
antigen
determin
melittin
respons
high
dc
matur
cellular
uptak
three
dose
biomimet
nanotoxoid
vaccin
mice
receiv
lethal
bolu
toxin
biomimet
nanotoxoid
vaccin
mice
show
surviv
rate
compar
surviv
rate
nonvaccin
mice
biomimet
nanospong
report
figur
use
plga
np
core
rbc
membran
surfac
coat
rbc
membran
act
substrat
pft
induc
alphatoxin
onto
surfac
reduc
hemolyt
activ
enhanc
blood
circul
time
footandmouth
diseas
fmd
highli
infecti
diseas
caus
fmd
virus
found
clovenhoof
anim
transmiss
anim
human
fmdv
vaccin
tradit
approach
timeconsum
expens
less
use
induc
suffici
mucos
immun
fmdv
np
wellknown
drug
carrier
antigen
adjuv
produc
strong
resist
teng
et
al
develop
fmd
vaccin
use
gold
nanostar
ausn
fmd
vlp
fmd
vlpsausn
complex
fmd
vlpsausn
nanovaccin
shown
figur
augment
robust
immun
respons
fmdv
biomimet
vaccin
manifest
high
cellular
uptak
due
vlp
modif
macrophag
activ
fmd
vlpsausn
rel
higher
vlp
aunp
nitric
oxid
product
induc
robust
immun
activ
fmdv
anoth
biomimet
nanovaccin
formul
use
synthet
peptid
deriv
fmdv
gold
np
aunp
synthet
peptid
capsid
protein
fmdv
strong
immun
activ
guinea
pig
higher
efficaci
compar
fmd
vaccin
footandmouth
diseas
fmd
highli
infecti
diseas
caus
fmd
virus
found
clovenhoof
anim
transmiss
anim
human
fmdv
vaccin
tradit
approach
timeconsum
expens
less
use
induc
suffici
mucos
immun
fmdv
np
wellknown
drug
carrier
antigen
adjuv
produc
strong
resist
teng
et
al
develop
fmd
vaccin
use
gold
nanostar
ausn
fmd
vlp
fmd
vlpsausn
complex
fmd
vlpsausn
nanovaccin
shown
figur
augment
robust
immun
respons
fmdv
biomimet
vaccin
manifest
high
cellular
uptak
due
vlp
modif
macrophag
activ
fmd
vlpsausn
rel
higher
vlp
aunp
nitric
oxid
product
induc
robust
immun
activ
fmdv
anoth
biomimet
nanovaccin
formul
use
synthet
peptid
deriv
fmdv
gold
np
aunp
synthet
peptid
capsid
protein
fmdv
strong
immun
activ
guinea
pig
higher
efficaci
compar
fmd
vaccin
footandmouth
diseas
fmd
highli
infecti
diseas
caus
fmd
virus
found
clovenhoof
anim
transmiss
anim
human
fmdv
vaccin
tradit
approach
timeconsum
expens
less
use
induc
suffici
mucos
immun
fmdv
np
wellknown
drug
carrier
antigen
adjuv
produc
strong
resist
teng
et
al
develop
fmd
vaccin
use
gold
nanostar
ausn
fmd
vlp
fmd
vlpsausn
complex
fmd
vlpsausn
nanovaccin
shown
figur
augment
robust
immun
respons
fmdv
biomimet
vaccin
manifest
high
cellular
uptak
due
vlp
modif
macrophag
activ
fmd
vlpsausn
rel
higher
vlp
aunp
nitric
oxid
product
induc
robust
immun
activ
fmdv
anoth
biomimet
nanovaccin
formul
use
synthet
peptid
deriv
fmdv
gold
np
aunp
synthet
peptid
capsid
protein
fmdv
strong
immun
activ
guinea
pig
higher
efficaci
compar
fmd
vaccin
tabl
summar
type
biomimet
np
therapeut
cargo
use
along
applic
treatment
variou
diseas
tabl
list
biomimet
nanovaccin
variou
treatment
liposom
hepa
cell
lysat
poli
c
high
tumor
specif
ctl
immun
respons
peptid
poli
c
ctl
immun
respons
anticanc
therapi
tumor
associ
antigen
receptor
target
anticanc
therapi
ova
antigen
ctl
respons
cancer
immun
therapi
endolysin
degrad
bacteri
protein
antibacteri
therapi
strong
antibodi
respons
antihiv
therapi
mper
mpla
sting
cdgmp
strong
tcell
respons
antihiv
therapi
activ
epiderm
apc
viru
like
np
cfp
ctl
activ
immun
respons
antibacteri
therapi
hiv
env
antigen
maintain
germin
center
releas
neutral
antibodi
antihiv
therapi
csphepat
b
surfac
antigen
matrixm
target
infect
erythrocyt
tcell
respons
antimalaria
therapi
antigen
type
antibodi
respons
anticanc
therapi
outer
membran
coat
nanovaccin
alum
adjuv
type
immun
respons
antibacteri
therapi
rbc
membran
coat
nanovaccin
none
adsorpt
bacteri
endotoxin
none
natur
substrat
pft
antimelittin
therapi
tcell
coat
nanovaccin
none
inhibit
viral
attack
host
cell
cancer
cell
membran
coat
nanovaccin
pdl
sirna
tumor
target
anticanc
therapi
cpg
oligodeoxynucleotid
stimul
apc
matur
releas
proinflammatori
cytokin
anticanc
therapi
poli
c
polyinosin
polycytidyl
acid
eso
cancer
multipl
antigen
peptideinterferon
envenvelop
glycoprotein
mpermembraneproxim
extern
region
mplamonophosphoryl
lipid
stingstimul
interferon
gene
human
epiderm
growth
factor
receptor
ova
ovalbumin
msp
merozoit
surfac
protein
filtrat
protein
although
nanovaccin
promin
model
treat
variou
diseas
efficaci
modul
immun
respons
diseas
except
disadvantag
biomimet
nanovaccin
base
stabil
purpos
liposom
storag
becom
major
drawback
lead
aggreg
structur
destabil
scale
nanovaccin
also
signific
challeng
due
stabil
well
costeffect
product
effici
manner
batch
batch
multipl
load
differ
compon
like
antigen
adjuv
singl
nanoplatform
difficult
becom
challeng
howev
demerit
biomimet
nanovaccin
subjug
appropri
idea
advanc
technolog
applic
biomimet
nanovaccin
remark
evolut
field
medicin
biomimet
nanovaccin
prime
attract
research
due
notabl
advantag
impress
research
outcom
alreadi
achiev
well
establish
knowledg
regard
physiolog
immunolog
behavior
diseas
base
design
strong
vaccin
biomimet
nanovaccin
stand
first
potenc
deliv
specif
onsit
deliveri
prolong
circul
reduc
sideeffect
induct
robust
immun
respons
final
nanovaccin
base
biomimet
principl
notic
advantag
like
biocompat
low
toxic
bioavail
target
lead
promin
agent
treat
variou
diseas
vaccin
candid
success
reach
clinic
preclin
evalu
vaccin
avail
market
elicit
humor
respons
therebi
avail
need
develop
vaccin
gener
strong
cellular
respons
certain
infecti
diseas
cancer
one
biomimet
nanovaccin
mosquirix
prove
effect
malaria
nanovaccin
constitut
circumsporozoit
protein
plasmodium
falciparum
mpla
saponin
adjuv
anoth
nanovaccin
current
clinic
trial
vaxfectin
cation
liposom
formul
encapsul
therapeut
dna
vaccin
herp
simplex
viru
vaxfectin
nanovaccin
also
use
dna
immun
influenza
viru
also
clinic
trial
anoth
fdaapprov
nanovaccin
inflex
v
ha
surfac
molecul
influenza
viru
directli
fuse
lipid
compon
use
subunit
influenza
vaccin
gener
modulu
membran
antigen
gmma
deriv
outer
membran
genet
modifi
gramneg
bacteria
produc
pentaacyl
lipopolysaccharid
vaccin
use
bacteri
infect
shigellosi
clinic
trial
addit
nanovaccin
mention
earlier
stimuvax
anoth
therapeut
liposom
vaccin
cancer
lipopeptid
call
tecemotid
use
antigen
target
specif
tumor
antigen
howev
vaccin
fail
iii
phase
clinic
trial
anoth
liposom
therapeut
vaccin
modifi
form
stimuvax
current
clinic
trial
nanovaccin
compos
synthet
peptid
antigen
mpla
immunoadjuv
lipid
anoth
biomimet
nanovaccin
epax
viral
liposom
nanovaccin
use
viral
glycoprotein
fuse
lipid
adjuv
use
hepat
infect
nanovaccin
attract
tremend
interest
past
year
due
uniqu
physicochem
characterist
role
nanovaccin
potent
vaccin
examin
boost
therapeut
activ
enhanc
stabil
prolong
circul
sitespecif
accumul
increas
deliveri
accord
variou
biolog
extern
stimulu
overcom
physiolog
barrier
activ
immunogen
materi
modul
immun
respons
nanovaccin
enabl
antigen
stabil
enhanc
antigen
process
immunogen
target
deliveri
prevent
burst
releas
antigen
adjuv
nanoscal
deliveri
vehicl
help
design
nanovaccin
elicit
potent
immun
respons
overcom
tumor
immunosuppress
biomimet
nanovaccin
emerg
promis
candid
multipl
function
singl
nanoplatform
biomimet
nanovaccin
enabl
codeliveri
antigen
adjuv
singl
platform
minim
side
effect
camouflag
properti
bio
membran
make
noteworthi
biomimet
nanovaccin
act
vaccin
variou
infecti
diseas
due
intrins
properti
bioinspir
nanovaccin
act
immunemodulatori
agent
stimul
dc
matur
cytotox
tcell
product
biocarri
nanovaccin
transport
antigen
adjuv
activ
drug
enhanc
antigen
present
immun
respons
activ
biomimet
nanovaccin
suitabl
epitop
produc
adequ
antibodi
neutral
antibodi
viral
parasit
infect
act
natur
substrat
adsorb
endotoxin
onto
surfac
reliev
infect
bodi
tumor
suppress
agent
rechalleng
nanovaccin
respons
cancer
cell
attun
erad
notwithstand
challeng
limit
biomimet
nanovaccin
advantag
mention
demonstr
nanovaccin
conquer
open
variou
novel
therapeut
modal
variou
diseas
